Lunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics

Reuters

2025/09/11

<a href="https://laohu8.com/S/RENB">Lunai Bioworks</a> Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

Lunai Bioworks Inc. (NASDAQ:RENB) has announced that its subsidiary, BioSymetrics Inc., in collaboration with Brigham and Women's Hospital, has been awarded a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The grant, valued at $1.85 million USD, is provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and is aimed at developing an AI-powered platform for drug discovery targeting Alcohol Use Disorder (AUD). This project, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, will utilize AI-driven behavioral phenotyping alongside large-scale drug screening models to address the urgent unmet therapeutic needs of AUD, a condition affecting over 19 million Americans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1071666) on September 11, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566967549"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566967549\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566967549?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566967549","market":"us","top_or_hot":-1,"title":"Lunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RENB\">Lunai Bioworks</a> Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lunai Bioworks Inc. (NASDAQ:RENB) has announced that its subsidiary, BioSymetrics Inc., in collaboration with Brigham and Women's Hospital, has been awarded a prestigious <a href=\"https://laohu8.com/S/SBDG\">Small Business</a> Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The grant, valued at $1.85 million USD, is provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and is aimed at developing an AI-powered platform for drug discovery targeting Alcohol Use Disorder (AUD). This project, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, will utilize AI-driven behavioral phenotyping alongside large-scale drug screening models to address the urgent unmet therapeutic needs of AUD, a condition affecting over 19 million Americans.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1071666) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-11 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RENB\">Lunai Bioworks</a> Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lunai Bioworks Inc. (NASDAQ:RENB) has announced that its subsidiary, BioSymetrics Inc., in collaboration with Brigham and Women's Hospital, has been awarded a prestigious <a href=\"https://laohu8.com/S/SBDG\">Small Business</a> Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The grant, valued at $1.85 million USD, is provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and is aimed at developing an AI-powered platform for drug discovery targeting Alcohol Use Disorder (AUD). This project, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, will utilize AI-driven behavioral phenotyping alongside large-scale drug screening models to address the urgent unmet therapeutic needs of AUD, a condition affecting over 19 million Americans.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1071666) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RENB","symbol_name":"Lunai Bioworks","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL3sdnPN:1","article_id":"2566967549","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566967549","pubTimestamp":1757588437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics. Lunai Bioworks Inc.  has announced that its subsidiary, BioSymetrics Inc., in collaboration with Brigham and Women's Hospital, has been awarded a prestigious Small Business Technology Transfer  grant from the National Institutes of Health . The grant, valued at $1.85 million USD, is provided by the National Institute on Alcohol Abuse and Alcoholism  and is aimed at developing an AI-powered platform for drug discovery targeting Alcohol Use Disorder . This project, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, will utilize AI-driven behavioral phenotyping alongside large-scale drug screening models to address the urgent unmet therapeutic needs of AUD, a condition affecting over 19 million Americans.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RENB":"Lunai Bioworks","BK4139":"生物科技"},"translate_title":"Lunai Bioworks子公司BioSymetrics和布莱根妇女医院获得185万美元的NIH STTR拨款，用于开发用于酒精使用障碍治疗的人工智能驱动平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RENB":0.9},"content_text":"Lunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics\n\n\n        Lunai Bioworks Inc. (NASDAQ:RENB) has announced that its subsidiary, BioSymetrics Inc., in collaboration with Brigham and Women's Hospital, has been awarded a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The grant, valued at $1.85 million USD, is provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and is aimed at developing an AI-powered platform for drug discovery targeting Alcohol Use Disorder (AUD). This project, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, will utilize AI-driven behavioral phenotyping alongside large-scale drug screening models to address the urgent unmet therapeutic needs of AUD, a condition affecting over 19 million Americans.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1071666) on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}